This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hirai, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, T.
Right arrow Articles by Hirai, H.

 Previous Article  |  Next Article 

Mol. Cell. Biol., May 1995, 2383-2392, Vol 15, No. 5
Copyright © 1995, American Society for Microbiology

Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias

T Tanaka, K Mitani, M Kurokawa, S Ogawa, K Tanaka, J Nishida, Y Yazaki, Y Shibata and H Hirai
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.

The chromosomal translocation t(3;21)(q26;q22), which is found in blastic crisis in chronic myelogenous leukemias and myelodysplastic syndrome-derived leukemias, produces AML1/Evi-1 chimeric transcription factor and is thought to play important roles in acute leukemic transformation of hemopoietic stem cells. We report here the functional analyses of AML1/Evi-1. It was revealed that AML1/Evi-1 itself does not alter the transactivation level through mouse polyomavirus enhancer- binding protein 2 (PEBP2; PEA2) sites (binding site of AML1) but dominantly suppresses the transactivation by intact AML1, which is assumed to be a stimulator of myeloid cell differentiation. DNA-binding competition is a putative mechanism of such dominant negative effects of AML1/Evi-1 because it binds to PEBP2 sites with higher affinity than AML1 does. Furthermore, AML1/Evi-1 stimulated c-fos promoter transactivation and increased AP-1 activity, as Evi-1 (which is not normally expressed in hemopoietic cells) did. Experiments using deletion mutants of AML1/Evi-1 showed that these two functions are mutually independent because the dominant negative effects on intact AML1 and the stimulation of AP-1 activity are dependent on the runt domain (DNA-binding domain of AML1) and the zinc finger domain near the C terminus, respectively. Furthermore, we showed that AML1/Evi-1 blocks granulocytic differentiation, otherwise induced by granulocyte colony- stimulating factor, of 32Dcl3 myeloid cells. It was also suggested that both AML1-derived and Evi-1-derived portions of the fusion protein play crucial roles in this differentiation block. We conclude that the leukemic cell transformation in t(3;21) leukemias is probably caused by these dual functions of AML1/Evi-1 chimeric protein.


This article has been cited by other articles:

  • Leventaki, V., Drakos, E., Medeiros, L. J., Lim, M. S., Elenitoba-Johnson, K. S., Claret, F. X., Rassidakis, G. Z. (2007). NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood 110: 1621-1630 [Abstract] [Full Text]  
  • Maki, K., Yamagata, T., Asai, T., Yamazaki, I., Oda, H., Hirai, H., Mitani, K. (2005). Dysplastic definitive hematopoiesis in AML1/EVI1 knock-in embryos. Blood 106: 2147-2155 [Abstract] [Full Text]  
  • Senyuk, V., Li, D., Zakharov, A., Mikhail, F. M., Nucifora, G. (2005). The Distal Zinc Finger Domain of AML1/MDS1/EVI1 Is an Oligomerization Domain Involved in Induction of Hematopoietic Differentiation Defects in Primary Cells In vitro. Cancer Res. 65: 7603-7611 [Abstract] [Full Text]  
  • Fukushima-Nakase, Y., Naoe, Y., Taniuchi, I., Hosoi, H., Sugimoto, T., Okuda, T. (2005). Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. Blood 105: 4298-4307 [Abstract] [Full Text]  
  • Helbling, D., Mueller, B. U., Timchenko, N. A., Hagemeijer, A., Jotterand, M., Meyer-Monard, S., Lister, A., Rowley, J. D., Huegli, B., Fey, M. F., Pabst, T. (2004). The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc. Natl. Acad. Sci. USA 101: 13312-13317 [Abstract] [Full Text]  
  • Calabretta, B., Perrotti, D. (2004). The biology of CML blast crisis. Blood 103: 4010-4022 [Abstract] [Full Text]  
  • Yamaguchi, Y., Kurokawa, M., Imai, Y., Izutsu, K., Asai, T., Ichikawa, M., Yamamoto, G., Nitta, E., Yamagata, T., Sasaki, K., Mitani, K., Ogawa, S., Chiba, S., Hirai, H. (2004). AML1 Is Functionally Regulated through p300-mediated Acetylation on Specific Lysine Residues. J. Biol. Chem. 279: 15630-15638 [Abstract] [Full Text]  
  • Nishimura, M., Fukushima-Nakase, Y., Fujita, Y., Nakao, M., Toda, S., Kitamura, N., Abe, T., Okuda, T. (2004). VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development. Blood 103: 562-570 [Abstract] [Full Text]  
  • Chen, J., Stinski, M. F. (2002). Role of Regulatory Elements and the MAPK/ERK or p38 MAPK Pathways for Activation of Human Cytomegalovirus Gene Expression. J. Virol. 76: 4873-4885 [Abstract] [Full Text]  
  • Lazarova, D. L., Bordonaro, M., Sartorelli, A. C. (2001). Transcriptional Regulation of the Vitamin D3 Receptor Gene by ZEB. Cell Growth Differ. 12: 319-326 [Abstract] [Full Text]  
  • Izutsu, K., Kurokawa, M., Imai, Y., Maki, K., Mitani, K., Hirai, H. (2001). The corepressor CtBP interacts with Evi-1 to repress transforming growth factor {beta} signaling. Blood 97: 2815-2822 [Abstract] [Full Text]  
  • Imai, Y., Kurokawa, M., Izutsu, K., Hangaishi, A., Takeuchi, K., Maki, K., Ogawa, S., Chiba, S., Mitani, K., Hirai, H. (2000). Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96: 3154-3160 [Abstract] [Full Text]  
  • Fredericks, W. J., Ayyanathan, K., Herlyn, M., Friedman, J. R., Rauscher, F. J. III (2000). An Engineered PAX3-KRAB Transcriptional Repressor Inhibits the Malignant Phenotype of Alveolar Rhabdomyosarcoma Cells Harboring the Endogenous PAX3-FKHR Oncogene. Mol. Cell. Biol. 20: 5019-5031 [Abstract] [Full Text]  
  • Kilbey, A., Stephens, V., Bartholomew, C. (1999). Loss of Cell Cycle Control by Deregulation of Cyclin-dependent Kinase 2 Kinase Activity in Evi-1 Transformed Fibroblasts. Cell Growth Differ. 10: 601-610 [Abstract] [Full Text]  
  • Kazama, H., Kodera, T., Shimizu, S., Mizoguchi, H., Morishita, K. (1999). Ecotropic Viral Integration Site-1 Is Activated during, and Is Sufficient for, Neuroectodermal P19 Cell Differentiation. Cell Growth Differ. 10: 565-573 [Abstract] [Full Text]  
  • Kramer, S., Jinks, T., Schedl, P, Gergen, J. (1999). Direct activation of Sex-lethal transcription by the Drosophila runt protein. Development 126: 191-200 [Abstract]  
  • Kurokawa, M., Mitani, K., Imai, Y., Ogawa, S., Yazaki, Y., Hirai, H. (1998). The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor-beta -Mediated Growth Inhibition of Myeloid Cells. Blood 92: 4003-4012 [Abstract] [Full Text]  
  • Tanaka, K., Tanaka, T., Kurokawa, M., Imai, Y., Ogawa, S., Mitani, K., Yazaki, Y., Hirai, H. (1998). The AML1/ETO(MTG8) and AML1/Evi-1 Leukemia-Associated Chimeric Oncoproteins Accumulate PEBP2beta (CBFbeta ) in the Nucleus More Efficiently Than Wild-Type AML1. Blood 91: 1688-1699 [Abstract] [Full Text]  
  • Stewart, M., Terry, A., Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., Onions, D. E., Neil, J. C. (1997). Proviral insertions induce the expression of bone-specific isoforms of PEBP2alpha A (CBFA1): Evidence for a new myc collaborating oncogene. Proc. Natl. Acad. Sci. USA 94: 8646-8651 [Abstract] [Full Text]  
  • Tenen, D. G., Hromas, R., Licht, J. D., Zhang, D.-E. (1997). Transcription Factors, Normal Myeloid Development, and Leukemia. Blood 90: 489-519 [Full Text]  
  • Klampfer, L., Zhang, J., Zelenetz, A. O., Uchida, H., Nimer, S. D. (1996). The AML1/ETO fusion protein activates transcription of BCL-2. Proc. Natl. Acad. Sci. USA 93: 14059-14064 [Abstract] [Full Text]  
  • Palmer, S., Brouillet, J.-P., Kilbey, A., Fulton, R., Walker, M., Crossley, M., Bartholomew, C. (2001). Evi-1 Transforming and Repressor Activities Are Mediated by CtBP Co-repressor Proteins. J. Biol. Chem. 276: 25834-25840 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»